• 心血管疾病论坛 • 上一篇    下一篇

老年原发性高血压合并糖尿病患者凝血纤溶功能变化的研究

王丽莉1,肖广辉1,诸葛欣1,陈翊玲2,杜卫京1   

  1. 1. 天津医科大学总医院干部病房
    2. Department of Biology, Old Dominion University, USA
  • 收稿日期:2011-09-26 修回日期:2011-10-24 出版日期:2012-02-15 发布日期:2012-02-15
  • 通讯作者: 肖广辉

Changes of coagulative and fibrinolytic function in patients with both hypertension and diabetes

  • Received:2011-09-26 Revised:2011-10-24 Published:2012-02-15 Online:2012-02-15

摘要: 目的:探讨老年原发性高血压合并2型糖尿病患者凝血纤溶功能的变化,防止血栓栓塞性并发症的发生。 方法:测定30例正常对照组、50例老年单纯原发性高血压患者和50例老年原发性高血压合并2型糖尿病患者的血浆血管性血友病因子(vWF: Ag)、纤维蛋白原(Fbg)、凝血酶原片段1+2(F1+2)、组织型纤溶酶原激活剂(t-PA)及其抑制物内皮细胞型纤溶酶原激活物抑制剂(PAI-1)水平,三组之间进行比较。结果:血浆vWF、FIB、F1+2、t-PA、PAI-1水平三组之间差异均有显著性意义(P<0.01)。高血压合并糖尿病组、高血压组和对照组比较,血浆vWF、FIB、F1+2、t-PA、PAI-1水平均有明显变化(P<0.01),高血压合并糖尿病组和高血压组比较,血浆F1+2、t-PA、PAI-1水平均有明显变化(P<0.05)。结论:老年原发性高血压合并2型糖尿病患者存在着凝血、纤溶功能紊乱,应定期监测上述指标,防止血栓栓塞性并发症的发生。

关键词: 高血压, 2型糖尿病, 凝血, 纤溶

Abstract: Objective:To investigate the changes of coagulative and fibrinolytic function in elderly patients with both hypertension and type 2 diabetes. Methods:Plasma levels of von Willebrand’s factor(vWF), fibrinogen(Fbg), prothombin fragment 1+2(F1+2), tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1)were detected in 50 patients with essential hypertension, 50 patients with both hypertension and type 2 diabetes and in 30 healthy controls. Results:The plasma levels of vWF, Fbg, F1+2, t-PA and PAI-1 had significant differences among groups (P <0.05).The hypertension and type 2 diabetes group, the hypertension group presented a significant difference to the control group for the plasma levels of vWF, Fbg, F1+2, t-PA, PAI-1. The levels of F1+2, t-PA and PAI-1 had significant differences in the hypertension and type 2 diabetes group compared with those in the hypertension group (P <0.05). Conclusions:There was coagulative and fibrinolytic disturbance in elderly patients with both hypertension and type 2 diabetes. Molecular markers should be measured in those patients for prevention and treatment of thrombotic diseases.

Key words: Hypertension, Type 2 diabetes, Coagulation, Fibrinolysis